The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?